Review



lambda phosphatase treatments  (New England Biolabs)


Bioz Verified Symbol New England Biolabs is a verified supplier
Bioz Manufacturer Symbol New England Biolabs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    New England Biolabs lambda phosphatase treatments
    TAK1 directly phosphorylates the NLRP1 DR at specific sites and requires a specific TST motif for NLRP1 inflammasome activation. A. Rhodamine labelled recombinant SNAP-tagged NLRP1-DR following PhosTag-SDS-Agarose-PAGE. Recombinant NLRP1-DR was incubated with recombinant ZAKα, p38α, and TAK1-TAB1 fusion in a standard kinase reaction for 60 minutes and labelled with SNAP ligand fluorescence (TMR-STAR). <t>Lambda</t> protein <t>phosphatase</t> or a negative control was spiked into each reaction, as indicated. Phosphorylated vs unphosphorylated species are indicated. B. IL-1β ELISA of NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), SATA 1-4, or STless mutants following treatment with 50 μM cantharidin or 1 μM anisomycin. Cell culture media was harvested after 8 hours of treatment. C. Recombinant SNAP-tagged NLRP1-DR was incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard kinase reaction for 60 minutes and mass spectrometry was used to detect phosphorylated peptides. Phosphorylated residues detected by mass spectrometry are indicated with solid dots while residues identified from the following add-back analysis are indicated with clear dots. Residues phosphorylated by TAK1 and ZAKα are indicated with blue and red respectively. D. Rhodamine labelled SNAP-tagged NLRP1-DR ‘Add-back’ mutants following PhosTag-SDS-Agarose-PAGE. In the STless background, indicated alanine residues were mutated back to serine or threonine. These recombinantly expressed mutants were incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard in vitro kinase reaction for 60 minutes. Phosphorylated vs unphosphorylated species for each protein is indicated. The crucial “TZ2” motif is highlighted in red. E. Immunoblot of cleaved PARP1, GSDMD (full length and cleaved), GSDME (full length and cleaved), GAPDH, Pro-IL-1β, cleaved IL-1β, and IL-18 (full length and cleaved) or F. IL-18 and IL-1β ELISA from NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), TZ2 mutant, or GFP control following treatment with 1 μM anisomycin, DMSO (vehicle control), and 50 μM cantharidin. Cells, floaters and cell culture media were harvested after 8 hours of treatment. Error bars represent SEM from three technical replicates, where one replicate refers to an independent sample. Significance values were calculated based on one-way ANOVA followed by Dunnett’s test for multiple pairwise comparisons (B) or two-way ANOVA followed by Sidak’s test for multiple pairwise comparisons (F). ns, nonsignificant; *P < 0.05; ****P < 0.0001.
    Lambda Phosphatase Treatments, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 2909 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/bio_rxiv__64898__2026__01__23__701189-412-1-9
    Average 99 stars, based on 2909 article reviews
    lambda phosphatase treatments - by Bioz Stars, 2026-09
    99/100 stars

    Images

    1) Product Images from "Two orthogonal MAP3K-driven pathways of NLRP1 inflammasome activation revealed by poisonous beetles"

    Article Title: Two orthogonal MAP3K-driven pathways of NLRP1 inflammasome activation revealed by poisonous beetles

    Journal: bioRxiv

    doi: 10.64898/2026.01.23.701189

    TAK1 directly phosphorylates the NLRP1 DR at specific sites and requires a specific TST motif for NLRP1 inflammasome activation. A. Rhodamine labelled recombinant SNAP-tagged NLRP1-DR following PhosTag-SDS-Agarose-PAGE. Recombinant NLRP1-DR was incubated with recombinant ZAKα, p38α, and TAK1-TAB1 fusion in a standard kinase reaction for 60 minutes and labelled with SNAP ligand fluorescence (TMR-STAR). Lambda protein phosphatase or a negative control was spiked into each reaction, as indicated. Phosphorylated vs unphosphorylated species are indicated. B. IL-1β ELISA of NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), SATA 1-4, or STless mutants following treatment with 50 μM cantharidin or 1 μM anisomycin. Cell culture media was harvested after 8 hours of treatment. C. Recombinant SNAP-tagged NLRP1-DR was incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard kinase reaction for 60 minutes and mass spectrometry was used to detect phosphorylated peptides. Phosphorylated residues detected by mass spectrometry are indicated with solid dots while residues identified from the following add-back analysis are indicated with clear dots. Residues phosphorylated by TAK1 and ZAKα are indicated with blue and red respectively. D. Rhodamine labelled SNAP-tagged NLRP1-DR ‘Add-back’ mutants following PhosTag-SDS-Agarose-PAGE. In the STless background, indicated alanine residues were mutated back to serine or threonine. These recombinantly expressed mutants were incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard in vitro kinase reaction for 60 minutes. Phosphorylated vs unphosphorylated species for each protein is indicated. The crucial “TZ2” motif is highlighted in red. E. Immunoblot of cleaved PARP1, GSDMD (full length and cleaved), GSDME (full length and cleaved), GAPDH, Pro-IL-1β, cleaved IL-1β, and IL-18 (full length and cleaved) or F. IL-18 and IL-1β ELISA from NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), TZ2 mutant, or GFP control following treatment with 1 μM anisomycin, DMSO (vehicle control), and 50 μM cantharidin. Cells, floaters and cell culture media were harvested after 8 hours of treatment. Error bars represent SEM from three technical replicates, where one replicate refers to an independent sample. Significance values were calculated based on one-way ANOVA followed by Dunnett’s test for multiple pairwise comparisons (B) or two-way ANOVA followed by Sidak’s test for multiple pairwise comparisons (F). ns, nonsignificant; *P < 0.05; ****P < 0.0001.
    Figure Legend Snippet: TAK1 directly phosphorylates the NLRP1 DR at specific sites and requires a specific TST motif for NLRP1 inflammasome activation. A. Rhodamine labelled recombinant SNAP-tagged NLRP1-DR following PhosTag-SDS-Agarose-PAGE. Recombinant NLRP1-DR was incubated with recombinant ZAKα, p38α, and TAK1-TAB1 fusion in a standard kinase reaction for 60 minutes and labelled with SNAP ligand fluorescence (TMR-STAR). Lambda protein phosphatase or a negative control was spiked into each reaction, as indicated. Phosphorylated vs unphosphorylated species are indicated. B. IL-1β ELISA of NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), SATA 1-4, or STless mutants following treatment with 50 μM cantharidin or 1 μM anisomycin. Cell culture media was harvested after 8 hours of treatment. C. Recombinant SNAP-tagged NLRP1-DR was incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard kinase reaction for 60 minutes and mass spectrometry was used to detect phosphorylated peptides. Phosphorylated residues detected by mass spectrometry are indicated with solid dots while residues identified from the following add-back analysis are indicated with clear dots. Residues phosphorylated by TAK1 and ZAKα are indicated with blue and red respectively. D. Rhodamine labelled SNAP-tagged NLRP1-DR ‘Add-back’ mutants following PhosTag-SDS-Agarose-PAGE. In the STless background, indicated alanine residues were mutated back to serine or threonine. These recombinantly expressed mutants were incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard in vitro kinase reaction for 60 minutes. Phosphorylated vs unphosphorylated species for each protein is indicated. The crucial “TZ2” motif is highlighted in red. E. Immunoblot of cleaved PARP1, GSDMD (full length and cleaved), GSDME (full length and cleaved), GAPDH, Pro-IL-1β, cleaved IL-1β, and IL-18 (full length and cleaved) or F. IL-18 and IL-1β ELISA from NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), TZ2 mutant, or GFP control following treatment with 1 μM anisomycin, DMSO (vehicle control), and 50 μM cantharidin. Cells, floaters and cell culture media were harvested after 8 hours of treatment. Error bars represent SEM from three technical replicates, where one replicate refers to an independent sample. Significance values were calculated based on one-way ANOVA followed by Dunnett’s test for multiple pairwise comparisons (B) or two-way ANOVA followed by Sidak’s test for multiple pairwise comparisons (F). ns, nonsignificant; *P < 0.05; ****P < 0.0001.

    Techniques Used: Activation Assay, Recombinant, Incubation, Fluorescence, Negative Control, Enzyme-linked Immunosorbent Assay, Cell Culture, Mass Spectrometry, In Vitro, Western Blot, Mutagenesis, Control

    Related Articles

    Incubation:

    Article Title: Protein phosphatase 1 regulates core PCP signaling
    Article Snippet: .. For λ phosphatase treatment, 2 μL of λ protein phosphatase (NEB P0753S) was added and incubated at 37°C for 30 minutes and then placed on ice. .. 20 μg total protein per lane was mixed with 4x LDS (Invitrogen) 200 mM DTT to a final of 1X LDS 50 mM DTT and incubated at 50°C for 15 minutes.

    Article Title: Activation of the Double-stranded RNA-dependent Protein Kinase PKR by Small Ubiquitin-like Modifier (SUMO)
    Article Snippet: The in vitro transcription/translation of proteins was performed by using 1 μg of plasmid DNA and a rabbit reticulocyte-coupled transcription/translation system according to the instructions provided by the manufacturer (Promega). .. In Vitro DeSUMOylation Assay In vitro deSUMOylation assay with GST-SENP1 was performed on PKR-SUMO1 as described previously ( 23 ). λ-Phosphatase Treatment SUMOylated PKR protein was incubated with 1 μl of λ-phosphatase (New England Biolabs) in buffer for λ-phosphatase treatment (50 m m Tris/HCl, pH 7.5, 100 m m NaCl, 0.1 m m EGTA, 2 m m DTT, 0.01% Brij 35) (New England Biolabs) supplemented with 2 m m MnCl 2 . ..

    Article Title: MRF Family Genes Are Involved in Translation Control, Especially under Energy-Deficient Conditions, and Their Expression and Functions Are Modulated by the TOR Signaling Pathway
    Article Snippet: Homogenized samples were resuspended in the same volume of extraction buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM DTT, and cOmplete protease inhibitor cocktail [Roche]). .. For the λ-phosphatase treatment, 10 mM MnCl 2 and either 400 units (1 μL) λ-phosphatase (New England Biolabs) or enzyme storage buffer (100 mM NaCl, 50 mM HEPES, pH 7.5, 0.1 mM MnCl 2 , 0.1 mM EGTA, 2 mM DTT, 0.01% Brij35, and 50% glycerol) was added to aliquots (21.5 μL) of protein extracts for incubation at 30°C for 1 h. The reaction was stopped by adding 3× protein sample buffer (200 mM Tris-HCl, pH 6.8, 3% SDS, 15% β-mercaptoethanol, 30% glycerol, 0.09% bromophenol blue, and 100 mM DTT), followed by incubation at 70°C for 10 min. Then the samples were subjected to 8% Zn 2+ -Phos-tag Bis-Tris NuPAGE with 50 μM ZnCl 2 and 50 μM Phos-taq system (Wako). ..

    Article Title: Phosphoregulation of Rad51/Rad52 by CDK1 functions as a molecular switch for cell cycle–specific activation of homologous recombination
    Article Snippet: Incorporation of 32 P was visualized using BAS-2500 (Bio-Rad) and Typhoon FLA 7000 (GE Healthcare). .. For λ phosphatase treatment, the Rad51 protein sample was incubated with 800 U of λ phosphatase (New England Biolabs) at 30°C for 3 hours. ..

    Article Title: Engineering a conserved immune coreceptor into a primed state enhances fungal resistance in crops without growth penalty.
    Article Snippet: Plants must tactically balance immunity and growth when combating lethal pathogens like fungi.. CHITIN ELICITOR RECEPTOR KINASE 1 (CERK1), a conserved cell-surface co-receptor for the fungal elicitor chitin, enables plants to induce chitin-triggered immunity to counteract fungal invasion.. Previously, we reported that bacterial infection can prime CERK1 through juxtamembrane (JM) phosphorylation to enhance fungal resistance, which only occurs in Arabidopsis (Arabidopsis thaliana) and its close relatives in Brassicaceae.

    Article Title: S6K2-mediated regulation of TRBP as a determinant of miRNA expression in human primary lymphatic endothelial cells
    Article Snippet: .. For λ phosphatase treatment, soluble protein lysates (10 μg) were incubated with or without λ phosphatase (400 U; NEB) for 45 min at 30°C. ..

    In Vitro:

    Article Title: Activation of the Double-stranded RNA-dependent Protein Kinase PKR by Small Ubiquitin-like Modifier (SUMO)
    Article Snippet: The in vitro transcription/translation of proteins was performed by using 1 μg of plasmid DNA and a rabbit reticulocyte-coupled transcription/translation system according to the instructions provided by the manufacturer (Promega). .. In Vitro DeSUMOylation Assay In vitro deSUMOylation assay with GST-SENP1 was performed on PKR-SUMO1 as described previously ( 23 ). λ-Phosphatase Treatment SUMOylated PKR protein was incubated with 1 μl of λ-phosphatase (New England Biolabs) in buffer for λ-phosphatase treatment (50 m m Tris/HCl, pH 7.5, 100 m m NaCl, 0.1 m m EGTA, 2 m m DTT, 0.01% Brij 35) (New England Biolabs) supplemented with 2 m m MnCl 2 . ..

    SDS Page:

    Article Title: Engineering a conserved immune coreceptor into a primed state enhances fungal resistance in crops without growth penalty.
    Article Snippet: Plants must tactically balance immunity and growth when combating lethal pathogens like fungi.. CHITIN ELICITOR RECEPTOR KINASE 1 (CERK1), a conserved cell-surface co-receptor for the fungal elicitor chitin, enables plants to induce chitin-triggered immunity to counteract fungal invasion.. Previously, we reported that bacterial infection can prime CERK1 through juxtamembrane (JM) phosphorylation to enhance fungal resistance, which only occurs in Arabidopsis (Arabidopsis thaliana) and its close relatives in Brassicaceae.



    Similar Products

    lambda phosphatase treatments  (New England Biolabs)
    99
    New England Biolabs lambda phosphatase treatments
    TAK1 directly phosphorylates the NLRP1 DR at specific sites and requires a specific TST motif for NLRP1 inflammasome activation. A. Rhodamine labelled recombinant SNAP-tagged NLRP1-DR following PhosTag-SDS-Agarose-PAGE. Recombinant NLRP1-DR was incubated with recombinant ZAKα, p38α, and TAK1-TAB1 fusion in a standard kinase reaction for 60 minutes and labelled with SNAP ligand fluorescence (TMR-STAR). <t>Lambda</t> protein <t>phosphatase</t> or a negative control was spiked into each reaction, as indicated. Phosphorylated vs unphosphorylated species are indicated. B. IL-1β ELISA of NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), SATA 1-4, or STless mutants following treatment with 50 μM cantharidin or 1 μM anisomycin. Cell culture media was harvested after 8 hours of treatment. C. Recombinant SNAP-tagged NLRP1-DR was incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard kinase reaction for 60 minutes and mass spectrometry was used to detect phosphorylated peptides. Phosphorylated residues detected by mass spectrometry are indicated with solid dots while residues identified from the following add-back analysis are indicated with clear dots. Residues phosphorylated by TAK1 and ZAKα are indicated with blue and red respectively. D. Rhodamine labelled SNAP-tagged NLRP1-DR ‘Add-back’ mutants following PhosTag-SDS-Agarose-PAGE. In the STless background, indicated alanine residues were mutated back to serine or threonine. These recombinantly expressed mutants were incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard in vitro kinase reaction for 60 minutes. Phosphorylated vs unphosphorylated species for each protein is indicated. The crucial “TZ2” motif is highlighted in red. E. Immunoblot of cleaved PARP1, GSDMD (full length and cleaved), GSDME (full length and cleaved), GAPDH, Pro-IL-1β, cleaved IL-1β, and IL-18 (full length and cleaved) or F. IL-18 and IL-1β ELISA from NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), TZ2 mutant, or GFP control following treatment with 1 μM anisomycin, DMSO (vehicle control), and 50 μM cantharidin. Cells, floaters and cell culture media were harvested after 8 hours of treatment. Error bars represent SEM from three technical replicates, where one replicate refers to an independent sample. Significance values were calculated based on one-way ANOVA followed by Dunnett’s test for multiple pairwise comparisons (B) or two-way ANOVA followed by Sidak’s test for multiple pairwise comparisons (F). ns, nonsignificant; *P < 0.05; ****P < 0.0001.
    Lambda Phosphatase Treatments, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/bio_rxiv__64898__2026__01__23__701189-412-1-9
    Average 99 stars, based on 1 article reviews
    lambda phosphatase treatments - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    phosphatase treatment  (New England Biolabs)
    99
    New England Biolabs phosphatase treatment
    (A) Overview of pS129-syn aggregate formation assay set-up. (B) Images of phosphorylated synuclein aggregates in SNCA Tri DNs. Two week old DNs are treated with 500 nM α-Syn PFFs or 500 nM α-Syn monomers.Two weeks after the treatment, DNs are fixed and stained for pS129-Syn and TUBB3. Bars = 100 μm. (C) Quantification of pS129-Syn aggregate formation. Total neurite area is identified and a mask for the neurite area is created from the TUBB3 channel image. Spots of pS129-Syn aggregates are identified in the pS129-Syn channel and analyzed within the TUBB3 neurite mask. (D) Confirmation of phosphorylated signal in DNs. DNs from the SNCA Tri line are differentiated for two weeks and then treated with 1 μM PFF for two weeks. After fixation, DNs on coverslips are treated with or without Lambda Protein <t>Phosphatase</t> prior to staining for pS129-Syn and TUBB3. bar = 100 μm. (E and F), Quantification of total pS129-Syn signal (E) and TUBB3 fluorescent signal (F) in SNCA_tri DNs; the data represents the mean±s.e.m. N=3 replicates.
    Phosphatase Treatment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/bio_rxiv__64898__2025__12__19__695578-69-4-20
    Average 99 stars, based on 1 article reviews
    phosphatase treatment - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    lambda protein phosphatase treatment  (New England Biolabs)
    99
    New England Biolabs lambda protein phosphatase treatment
    (A) Phos-tag™ SDS-PAGE (upper panel) and standard SDS-PAGE (lower panel) followed by WB of CLK1. Migration of different phosphorylation states is shown on the right. <t>Lambda</t> <t>phosphatase</t> treated sample (+Lambda pp) was used as a reference for dephosphorylated CLK1. DMSO or RIOK2 inhibitors (CQ211, 20 μM; NSC139021, 30 μM) were added during recovery. (B) Schematic of the CLK1 peptide spanning amino acids (aa) 323–343 and bar graph showing the abundance of the phosphorylated peptide across temperature conditions. DMSO or RIOK2 inhibitors were added during recovery as in (A). “1x Phospho” denotes phosphorylation at a single Ser/Thr/Tyr residue. n.d., below the detection limit. Data are presented as mean ± SD (n = 3), with each sample measured twice by mass spectrometry and averaged. **** p < 0.0001, *0.01 < p < 0.05 (Šidák’s multiple comparisons test). (C, E) Subnuclear localization of CLK1 mutants under thermal stress and recovery, visualized by HSATIII RNA-FISH combined with FLAG IF. (C) S/T→A mutant carries alanine substitutions at all serine/threonine residues within CLK1 aa 323-343 (S328A/S330A/S337A/T338A/S341A/T342A). (E) DMSO or CQ211 (10 μM) was added during recovery. Scale bar, 10 μm. (D, F) Quantification of colocalization between CLK1 mutants and nSBs (n = 30) in (C, E). **** p < 0.0001, *0.01 < p < 0.05 (Dunn’s multiple comparisons test). (G) In vitro phosphorylation of RIOK2 and CLK1 assessed by autoradiography with WB validation. (H) Quantification of autoradiographic signal intensities from (G). Each bar corresponds to the lane numbers shown in (G). Data are presented as mean ± SD (n = 3). **** p < 0.0001, ***0.0001 < p < 0.001 (Šidák’s multiple comparisons test).
    Lambda Protein Phosphatase Treatment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/bio_rxiv__2025__10__21__683800-301-1-16
    Average 99 stars, based on 1 article reviews
    lambda protein phosphatase treatment - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    lambda protein phosphatase λpp treatment  (New England Biolabs)
    99
    New England Biolabs lambda protein phosphatase λpp treatment
    (A) Phos-tag™ SDS-PAGE (upper panel) and standard SDS-PAGE (lower panel) followed by WB of CLK1. Migration of different phosphorylation states is shown on the right. <t>Lambda</t> <t>phosphatase</t> treated sample (+Lambda pp) was used as a reference for dephosphorylated CLK1. DMSO or RIOK2 inhibitors (CQ211, 20 μM; NSC139021, 30 μM) were added during recovery. (B) Schematic of the CLK1 peptide spanning amino acids (aa) 323–343 and bar graph showing the abundance of the phosphorylated peptide across temperature conditions. DMSO or RIOK2 inhibitors were added during recovery as in (A). “1x Phospho” denotes phosphorylation at a single Ser/Thr/Tyr residue. n.d., below the detection limit. Data are presented as mean ± SD (n = 3), with each sample measured twice by mass spectrometry and averaged. **** p < 0.0001, *0.01 < p < 0.05 (Šidák’s multiple comparisons test). (C, E) Subnuclear localization of CLK1 mutants under thermal stress and recovery, visualized by HSATIII RNA-FISH combined with FLAG IF. (C) S/T→A mutant carries alanine substitutions at all serine/threonine residues within CLK1 aa 323-343 (S328A/S330A/S337A/T338A/S341A/T342A). (E) DMSO or CQ211 (10 μM) was added during recovery. Scale bar, 10 μm. (D, F) Quantification of colocalization between CLK1 mutants and nSBs (n = 30) in (C, E). **** p < 0.0001, *0.01 < p < 0.05 (Dunn’s multiple comparisons test). (G) In vitro phosphorylation of RIOK2 and CLK1 assessed by autoradiography with WB validation. (H) Quantification of autoradiographic signal intensities from (G). Each bar corresponds to the lane numbers shown in (G). Data are presented as mean ± SD (n = 3). **** p < 0.0001, ***0.0001 < p < 0.001 (Šidák’s multiple comparisons test).
    Lambda Protein Phosphatase λpp Treatment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/pm40676839-335-9-20
    Average 99 stars, based on 1 article reviews
    lambda protein phosphatase λpp treatment - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    lambda protein phosphatase λppase treatment  (New England Biolabs)
    99
    New England Biolabs lambda protein phosphatase λppase treatment
    (A) Phos-tag™ SDS-PAGE (upper panel) and standard SDS-PAGE (lower panel) followed by WB of CLK1. Migration of different phosphorylation states is shown on the right. <t>Lambda</t> <t>phosphatase</t> treated sample (+Lambda pp) was used as a reference for dephosphorylated CLK1. DMSO or RIOK2 inhibitors (CQ211, 20 μM; NSC139021, 30 μM) were added during recovery. (B) Schematic of the CLK1 peptide spanning amino acids (aa) 323–343 and bar graph showing the abundance of the phosphorylated peptide across temperature conditions. DMSO or RIOK2 inhibitors were added during recovery as in (A). “1x Phospho” denotes phosphorylation at a single Ser/Thr/Tyr residue. n.d., below the detection limit. Data are presented as mean ± SD (n = 3), with each sample measured twice by mass spectrometry and averaged. **** p < 0.0001, *0.01 < p < 0.05 (Šidák’s multiple comparisons test). (C, E) Subnuclear localization of CLK1 mutants under thermal stress and recovery, visualized by HSATIII RNA-FISH combined with FLAG IF. (C) S/T→A mutant carries alanine substitutions at all serine/threonine residues within CLK1 aa 323-343 (S328A/S330A/S337A/T338A/S341A/T342A). (E) DMSO or CQ211 (10 μM) was added during recovery. Scale bar, 10 μm. (D, F) Quantification of colocalization between CLK1 mutants and nSBs (n = 30) in (C, E). **** p < 0.0001, *0.01 < p < 0.05 (Dunn’s multiple comparisons test). (G) In vitro phosphorylation of RIOK2 and CLK1 assessed by autoradiography with WB validation. (H) Quantification of autoradiographic signal intensities from (G). Each bar corresponds to the lane numbers shown in (G). Data are presented as mean ± SD (n = 3). **** p < 0.0001, ***0.0001 < p < 0.001 (Šidák’s multiple comparisons test).
    Lambda Protein Phosphatase λppase Treatment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/10__7554_slash_elife__97189-389-5-41
    Average 99 stars, based on 1 article reviews
    lambda protein phosphatase λppase treatment - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    lambda phosphatase treatment  (New England Biolabs)
    99
    New England Biolabs lambda phosphatase treatment
    (A) Phos-tag™ SDS-PAGE (upper panel) and standard SDS-PAGE (lower panel) followed by WB of CLK1. Migration of different phosphorylation states is shown on the right. <t>Lambda</t> <t>phosphatase</t> treated sample (+Lambda pp) was used as a reference for dephosphorylated CLK1. DMSO or RIOK2 inhibitors (CQ211, 20 μM; NSC139021, 30 μM) were added during recovery. (B) Schematic of the CLK1 peptide spanning amino acids (aa) 323–343 and bar graph showing the abundance of the phosphorylated peptide across temperature conditions. DMSO or RIOK2 inhibitors were added during recovery as in (A). “1x Phospho” denotes phosphorylation at a single Ser/Thr/Tyr residue. n.d., below the detection limit. Data are presented as mean ± SD (n = 3), with each sample measured twice by mass spectrometry and averaged. **** p < 0.0001, *0.01 < p < 0.05 (Šidák’s multiple comparisons test). (C, E) Subnuclear localization of CLK1 mutants under thermal stress and recovery, visualized by HSATIII RNA-FISH combined with FLAG IF. (C) S/T→A mutant carries alanine substitutions at all serine/threonine residues within CLK1 aa 323-343 (S328A/S330A/S337A/T338A/S341A/T342A). (E) DMSO or CQ211 (10 μM) was added during recovery. Scale bar, 10 μm. (D, F) Quantification of colocalization between CLK1 mutants and nSBs (n = 30) in (C, E). **** p < 0.0001, *0.01 < p < 0.05 (Dunn’s multiple comparisons test). (G) In vitro phosphorylation of RIOK2 and CLK1 assessed by autoradiography with WB validation. (H) Quantification of autoradiographic signal intensities from (G). Each bar corresponds to the lane numbers shown in (G). Data are presented as mean ± SD (n = 3). **** p < 0.0001, ***0.0001 < p < 0.001 (Šidák’s multiple comparisons test).
    Lambda Phosphatase Treatment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/pmc11685634-438-0-8
    Average 99 stars, based on 1 article reviews
    lambda phosphatase treatment - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    λ phosphatase treatment  (New England Biolabs)
    99
    New England Biolabs λ phosphatase treatment
    (A) Phos-tag™ SDS-PAGE (upper panel) and standard SDS-PAGE (lower panel) followed by WB of CLK1. Migration of different phosphorylation states is shown on the right. <t>Lambda</t> <t>phosphatase</t> treated sample (+Lambda pp) was used as a reference for dephosphorylated CLK1. DMSO or RIOK2 inhibitors (CQ211, 20 μM; NSC139021, 30 μM) were added during recovery. (B) Schematic of the CLK1 peptide spanning amino acids (aa) 323–343 and bar graph showing the abundance of the phosphorylated peptide across temperature conditions. DMSO or RIOK2 inhibitors were added during recovery as in (A). “1x Phospho” denotes phosphorylation at a single Ser/Thr/Tyr residue. n.d., below the detection limit. Data are presented as mean ± SD (n = 3), with each sample measured twice by mass spectrometry and averaged. **** p < 0.0001, *0.01 < p < 0.05 (Šidák’s multiple comparisons test). (C, E) Subnuclear localization of CLK1 mutants under thermal stress and recovery, visualized by HSATIII RNA-FISH combined with FLAG IF. (C) S/T→A mutant carries alanine substitutions at all serine/threonine residues within CLK1 aa 323-343 (S328A/S330A/S337A/T338A/S341A/T342A). (E) DMSO or CQ211 (10 μM) was added during recovery. Scale bar, 10 μm. (D, F) Quantification of colocalization between CLK1 mutants and nSBs (n = 30) in (C, E). **** p < 0.0001, *0.01 < p < 0.05 (Dunn’s multiple comparisons test). (G) In vitro phosphorylation of RIOK2 and CLK1 assessed by autoradiography with WB validation. (H) Quantification of autoradiographic signal intensities from (G). Each bar corresponds to the lane numbers shown in (G). Data are presented as mean ± SD (n = 3). **** p < 0.0001, ***0.0001 < p < 0.001 (Šidák’s multiple comparisons test).
    λ Phosphatase Treatment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/pm39321183-382-1-10
    Average 99 stars, based on 1 article reviews
    λ phosphatase treatment - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    nocodazole treatment  (New England Biolabs)
    99
    New England Biolabs nocodazole treatment
    (A) Phos-tag™ SDS-PAGE (upper panel) and standard SDS-PAGE (lower panel) followed by WB of CLK1. Migration of different phosphorylation states is shown on the right. <t>Lambda</t> <t>phosphatase</t> treated sample (+Lambda pp) was used as a reference for dephosphorylated CLK1. DMSO or RIOK2 inhibitors (CQ211, 20 μM; NSC139021, 30 μM) were added during recovery. (B) Schematic of the CLK1 peptide spanning amino acids (aa) 323–343 and bar graph showing the abundance of the phosphorylated peptide across temperature conditions. DMSO or RIOK2 inhibitors were added during recovery as in (A). “1x Phospho” denotes phosphorylation at a single Ser/Thr/Tyr residue. n.d., below the detection limit. Data are presented as mean ± SD (n = 3), with each sample measured twice by mass spectrometry and averaged. **** p < 0.0001, *0.01 < p < 0.05 (Šidák’s multiple comparisons test). (C, E) Subnuclear localization of CLK1 mutants under thermal stress and recovery, visualized by HSATIII RNA-FISH combined with FLAG IF. (C) S/T→A mutant carries alanine substitutions at all serine/threonine residues within CLK1 aa 323-343 (S328A/S330A/S337A/T338A/S341A/T342A). (E) DMSO or CQ211 (10 μM) was added during recovery. Scale bar, 10 μm. (D, F) Quantification of colocalization between CLK1 mutants and nSBs (n = 30) in (C, E). **** p < 0.0001, *0.01 < p < 0.05 (Dunn’s multiple comparisons test). (G) In vitro phosphorylation of RIOK2 and CLK1 assessed by autoradiography with WB validation. (H) Quantification of autoradiographic signal intensities from (G). Each bar corresponds to the lane numbers shown in (G). Data are presented as mean ± SD (n = 3). **** p < 0.0001, ***0.0001 < p < 0.001 (Šidák’s multiple comparisons test).
    Nocodazole Treatment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%BB+phosphatase+treatment/Lambda+Protein+Phosphatase/pm39014228-245-47-60
    Average 99 stars, based on 1 article reviews
    nocodazole treatment - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    TAK1 directly phosphorylates the NLRP1 DR at specific sites and requires a specific TST motif for NLRP1 inflammasome activation. A. Rhodamine labelled recombinant SNAP-tagged NLRP1-DR following PhosTag-SDS-Agarose-PAGE. Recombinant NLRP1-DR was incubated with recombinant ZAKα, p38α, and TAK1-TAB1 fusion in a standard kinase reaction for 60 minutes and labelled with SNAP ligand fluorescence (TMR-STAR). Lambda protein phosphatase or a negative control was spiked into each reaction, as indicated. Phosphorylated vs unphosphorylated species are indicated. B. IL-1β ELISA of NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), SATA 1-4, or STless mutants following treatment with 50 μM cantharidin or 1 μM anisomycin. Cell culture media was harvested after 8 hours of treatment. C. Recombinant SNAP-tagged NLRP1-DR was incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard kinase reaction for 60 minutes and mass spectrometry was used to detect phosphorylated peptides. Phosphorylated residues detected by mass spectrometry are indicated with solid dots while residues identified from the following add-back analysis are indicated with clear dots. Residues phosphorylated by TAK1 and ZAKα are indicated with blue and red respectively. D. Rhodamine labelled SNAP-tagged NLRP1-DR ‘Add-back’ mutants following PhosTag-SDS-Agarose-PAGE. In the STless background, indicated alanine residues were mutated back to serine or threonine. These recombinantly expressed mutants were incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard in vitro kinase reaction for 60 minutes. Phosphorylated vs unphosphorylated species for each protein is indicated. The crucial “TZ2” motif is highlighted in red. E. Immunoblot of cleaved PARP1, GSDMD (full length and cleaved), GSDME (full length and cleaved), GAPDH, Pro-IL-1β, cleaved IL-1β, and IL-18 (full length and cleaved) or F. IL-18 and IL-1β ELISA from NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), TZ2 mutant, or GFP control following treatment with 1 μM anisomycin, DMSO (vehicle control), and 50 μM cantharidin. Cells, floaters and cell culture media were harvested after 8 hours of treatment. Error bars represent SEM from three technical replicates, where one replicate refers to an independent sample. Significance values were calculated based on one-way ANOVA followed by Dunnett’s test for multiple pairwise comparisons (B) or two-way ANOVA followed by Sidak’s test for multiple pairwise comparisons (F). ns, nonsignificant; *P < 0.05; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Two orthogonal MAP3K-driven pathways of NLRP1 inflammasome activation revealed by poisonous beetles

    doi: 10.64898/2026.01.23.701189

    Figure Lengend Snippet: TAK1 directly phosphorylates the NLRP1 DR at specific sites and requires a specific TST motif for NLRP1 inflammasome activation. A. Rhodamine labelled recombinant SNAP-tagged NLRP1-DR following PhosTag-SDS-Agarose-PAGE. Recombinant NLRP1-DR was incubated with recombinant ZAKα, p38α, and TAK1-TAB1 fusion in a standard kinase reaction for 60 minutes and labelled with SNAP ligand fluorescence (TMR-STAR). Lambda protein phosphatase or a negative control was spiked into each reaction, as indicated. Phosphorylated vs unphosphorylated species are indicated. B. IL-1β ELISA of NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), SATA 1-4, or STless mutants following treatment with 50 μM cantharidin or 1 μM anisomycin. Cell culture media was harvested after 8 hours of treatment. C. Recombinant SNAP-tagged NLRP1-DR was incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard kinase reaction for 60 minutes and mass spectrometry was used to detect phosphorylated peptides. Phosphorylated residues detected by mass spectrometry are indicated with solid dots while residues identified from the following add-back analysis are indicated with clear dots. Residues phosphorylated by TAK1 and ZAKα are indicated with blue and red respectively. D. Rhodamine labelled SNAP-tagged NLRP1-DR ‘Add-back’ mutants following PhosTag-SDS-Agarose-PAGE. In the STless background, indicated alanine residues were mutated back to serine or threonine. These recombinantly expressed mutants were incubated with recombinant TAK1-TAB1 fusion or ZAKα in a standard in vitro kinase reaction for 60 minutes. Phosphorylated vs unphosphorylated species for each protein is indicated. The crucial “TZ2” motif is highlighted in red. E. Immunoblot of cleaved PARP1, GSDMD (full length and cleaved), GSDME (full length and cleaved), GAPDH, Pro-IL-1β, cleaved IL-1β, and IL-18 (full length and cleaved) or F. IL-18 and IL-1β ELISA from NLRP1 KO N/TERTs overexpressing GFP_NLRP1-86-C_FLAG (WT), TZ2 mutant, or GFP control following treatment with 1 μM anisomycin, DMSO (vehicle control), and 50 μM cantharidin. Cells, floaters and cell culture media were harvested after 8 hours of treatment. Error bars represent SEM from three technical replicates, where one replicate refers to an independent sample. Significance values were calculated based on one-way ANOVA followed by Dunnett’s test for multiple pairwise comparisons (B) or two-way ANOVA followed by Sidak’s test for multiple pairwise comparisons (F). ns, nonsignificant; *P < 0.05; ****P < 0.0001.

    Article Snippet: For lambda phosphatase treatments, a final concentration of 1X NEBuffer for Protein MetalloPhosphatases (PMP), 1 mM MnCl 2 , and 0.4 μL of Lambda Protein Phosphatase (NEB, P0753S) was added to the reaction mix and incubated at 30 °C for 30 minutes.

    Techniques: Activation Assay, Recombinant, Incubation, Fluorescence, Negative Control, Enzyme-linked Immunosorbent Assay, Cell Culture, Mass Spectrometry, In Vitro, Western Blot, Mutagenesis, Control

    (A) Overview of pS129-syn aggregate formation assay set-up. (B) Images of phosphorylated synuclein aggregates in SNCA Tri DNs. Two week old DNs are treated with 500 nM α-Syn PFFs or 500 nM α-Syn monomers.Two weeks after the treatment, DNs are fixed and stained for pS129-Syn and TUBB3. Bars = 100 μm. (C) Quantification of pS129-Syn aggregate formation. Total neurite area is identified and a mask for the neurite area is created from the TUBB3 channel image. Spots of pS129-Syn aggregates are identified in the pS129-Syn channel and analyzed within the TUBB3 neurite mask. (D) Confirmation of phosphorylated signal in DNs. DNs from the SNCA Tri line are differentiated for two weeks and then treated with 1 μM PFF for two weeks. After fixation, DNs on coverslips are treated with or without Lambda Protein Phosphatase prior to staining for pS129-Syn and TUBB3. bar = 100 μm. (E and F), Quantification of total pS129-Syn signal (E) and TUBB3 fluorescent signal (F) in SNCA_tri DNs; the data represents the mean±s.e.m. N=3 replicates.

    Journal: bioRxiv

    Article Title: An automated workflow for quantifying the formation of synuclein aggregates in human dopaminergic neurons

    doi: 10.64898/2025.12.19.695578

    Figure Lengend Snippet: (A) Overview of pS129-syn aggregate formation assay set-up. (B) Images of phosphorylated synuclein aggregates in SNCA Tri DNs. Two week old DNs are treated with 500 nM α-Syn PFFs or 500 nM α-Syn monomers.Two weeks after the treatment, DNs are fixed and stained for pS129-Syn and TUBB3. Bars = 100 μm. (C) Quantification of pS129-Syn aggregate formation. Total neurite area is identified and a mask for the neurite area is created from the TUBB3 channel image. Spots of pS129-Syn aggregates are identified in the pS129-Syn channel and analyzed within the TUBB3 neurite mask. (D) Confirmation of phosphorylated signal in DNs. DNs from the SNCA Tri line are differentiated for two weeks and then treated with 1 μM PFF for two weeks. After fixation, DNs on coverslips are treated with or without Lambda Protein Phosphatase prior to staining for pS129-Syn and TUBB3. bar = 100 μm. (E and F), Quantification of total pS129-Syn signal (E) and TUBB3 fluorescent signal (F) in SNCA_tri DNs; the data represents the mean±s.e.m. N=3 replicates.

    Article Snippet: For samples subjected to phosphatase treatment, cells were fixed and permeabilized and then incubated with 50 units/μL Lambda protein phosphatase (New England Biolabs, cat P0753L) at 30°C for 8 hours before IF staining.

    Techniques: Tube Formation Assay, Staining

    (A) Phos-tag™ SDS-PAGE (upper panel) and standard SDS-PAGE (lower panel) followed by WB of CLK1. Migration of different phosphorylation states is shown on the right. Lambda phosphatase treated sample (+Lambda pp) was used as a reference for dephosphorylated CLK1. DMSO or RIOK2 inhibitors (CQ211, 20 μM; NSC139021, 30 μM) were added during recovery. (B) Schematic of the CLK1 peptide spanning amino acids (aa) 323–343 and bar graph showing the abundance of the phosphorylated peptide across temperature conditions. DMSO or RIOK2 inhibitors were added during recovery as in (A). “1x Phospho” denotes phosphorylation at a single Ser/Thr/Tyr residue. n.d., below the detection limit. Data are presented as mean ± SD (n = 3), with each sample measured twice by mass spectrometry and averaged. **** p < 0.0001, *0.01 < p < 0.05 (Šidák’s multiple comparisons test). (C, E) Subnuclear localization of CLK1 mutants under thermal stress and recovery, visualized by HSATIII RNA-FISH combined with FLAG IF. (C) S/T→A mutant carries alanine substitutions at all serine/threonine residues within CLK1 aa 323-343 (S328A/S330A/S337A/T338A/S341A/T342A). (E) DMSO or CQ211 (10 μM) was added during recovery. Scale bar, 10 μm. (D, F) Quantification of colocalization between CLK1 mutants and nSBs (n = 30) in (C, E). **** p < 0.0001, *0.01 < p < 0.05 (Dunn’s multiple comparisons test). (G) In vitro phosphorylation of RIOK2 and CLK1 assessed by autoradiography with WB validation. (H) Quantification of autoradiographic signal intensities from (G). Each bar corresponds to the lane numbers shown in (G). Data are presented as mean ± SD (n = 3). **** p < 0.0001, ***0.0001 < p < 0.001 (Šidák’s multiple comparisons test).

    Journal: bioRxiv

    Article Title: Thermo-Sensing Mechanisms of Splicing Control by Nuclear Stress Bodies

    doi: 10.1101/2025.10.21.683800

    Figure Lengend Snippet: (A) Phos-tag™ SDS-PAGE (upper panel) and standard SDS-PAGE (lower panel) followed by WB of CLK1. Migration of different phosphorylation states is shown on the right. Lambda phosphatase treated sample (+Lambda pp) was used as a reference for dephosphorylated CLK1. DMSO or RIOK2 inhibitors (CQ211, 20 μM; NSC139021, 30 μM) were added during recovery. (B) Schematic of the CLK1 peptide spanning amino acids (aa) 323–343 and bar graph showing the abundance of the phosphorylated peptide across temperature conditions. DMSO or RIOK2 inhibitors were added during recovery as in (A). “1x Phospho” denotes phosphorylation at a single Ser/Thr/Tyr residue. n.d., below the detection limit. Data are presented as mean ± SD (n = 3), with each sample measured twice by mass spectrometry and averaged. **** p < 0.0001, *0.01 < p < 0.05 (Šidák’s multiple comparisons test). (C, E) Subnuclear localization of CLK1 mutants under thermal stress and recovery, visualized by HSATIII RNA-FISH combined with FLAG IF. (C) S/T→A mutant carries alanine substitutions at all serine/threonine residues within CLK1 aa 323-343 (S328A/S330A/S337A/T338A/S341A/T342A). (E) DMSO or CQ211 (10 μM) was added during recovery. Scale bar, 10 μm. (D, F) Quantification of colocalization between CLK1 mutants and nSBs (n = 30) in (C, E). **** p < 0.0001, *0.01 < p < 0.05 (Dunn’s multiple comparisons test). (G) In vitro phosphorylation of RIOK2 and CLK1 assessed by autoradiography with WB validation. (H) Quantification of autoradiographic signal intensities from (G). Each bar corresponds to the lane numbers shown in (G). Data are presented as mean ± SD (n = 3). **** p < 0.0001, ***0.0001 < p < 0.001 (Šidák’s multiple comparisons test).

    Article Snippet: For Lambda protein phosphatase treatment, cells expressing FLAG-tagged CLK1 were washed with PBS and lysed in NEBuffer for PMP (NEB) containing 0.1% NP-40.

    Techniques: SDS Page, Migration, Phospho-proteomics, Residue, Mass Spectrometry, Mutagenesis, In Vitro, Autoradiography, Biomarker Discovery